CA3207854A1 - Heterocyclic compounds and uses thereof - Google Patents
Heterocyclic compounds and uses thereof Download PDFInfo
- Publication number
- CA3207854A1 CA3207854A1 CA3207854A CA3207854A CA3207854A1 CA 3207854 A1 CA3207854 A1 CA 3207854A1 CA 3207854 A CA3207854 A CA 3207854A CA 3207854 A CA3207854 A CA 3207854A CA 3207854 A1 CA3207854 A1 CA 3207854A1
- Authority
- CA
- Canada
- Prior art keywords
- independently selected
- solvate
- pharmaceutically acceptable
- acceptable salt
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163147713P | 2021-02-09 | 2021-02-09 | |
| US202163147712P | 2021-02-09 | 2021-02-09 | |
| US63/147,712 | 2021-02-09 | ||
| US63/147,713 | 2021-02-09 | ||
| US202163166224P | 2021-03-25 | 2021-03-25 | |
| US63/166,224 | 2021-03-25 | ||
| US202163176866P | 2021-04-19 | 2021-04-19 | |
| US63/176,866 | 2021-04-19 | ||
| US202163191910P | 2021-05-21 | 2021-05-21 | |
| US63/191,910 | 2021-05-21 | ||
| PCT/US2022/015874 WO2022173870A1 (en) | 2021-02-09 | 2022-02-09 | Heterocyclic compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3207854A1 true CA3207854A1 (en) | 2022-08-18 |
Family
ID=82837902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3207854A Pending CA3207854A1 (en) | 2021-02-09 | 2022-02-09 | Heterocyclic compounds and uses thereof |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240254129A1 (https=) |
| EP (1) | EP4291199A4 (https=) |
| JP (1) | JP2024506329A (https=) |
| AU (1) | AU2022220678A1 (https=) |
| CA (1) | CA3207854A1 (https=) |
| WO (1) | WO2022173870A1 (https=) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
| UA129778C2 (uk) | 2019-10-28 | 2025-07-30 | Мерк Шарп Енд Доум Елелсі | Низькомолекулярні інгібітори g12c-мутантного kras |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| CA3191279A1 (en) | 2020-08-28 | 2022-03-03 | Yi Liu | Heterocyclic compounds and uses thereof |
| CA3203080A1 (en) * | 2020-12-22 | 2022-06-30 | Hongqi Tian | Preparation and application method of heterocyclic compound as kras inhibitor |
| JP2024510207A (ja) * | 2021-03-12 | 2024-03-06 | ブリストル－マイヤーズ スクイブ カンパニー | Ｋｒａｓ阻害剤 |
| CN117659051A (zh) * | 2021-03-30 | 2024-03-08 | 上海德琪医药科技有限公司 | Kras g12d蛋白抑制剂和其用途 |
| US20250059205A1 (en) * | 2021-04-29 | 2025-02-20 | Amgen Inc. | Heterocyclic Compounds and Methods of Use |
| MX2023012725A (es) * | 2021-04-29 | 2024-09-23 | Amgen Inc | Compuestos de 2-aminobenzotiazol y metodos de uso de los mismos. |
| US20230391785A1 (en) * | 2021-05-24 | 2023-12-07 | 280 Bio, Inc. | Nitrogen-containing heterocyclic compound, method for preparing same and use of same |
| WO2023284881A1 (en) * | 2021-07-16 | 2023-01-19 | Silexon Ai Technology Co., Ltd. | Heterocyclic compounds useful as kras g12d inhibitors |
| UY39906A (es) * | 2021-08-18 | 2023-03-31 | Jacobio Pharmaceuticals Co Ltd | Derivados de 1,4-oxazepano y usos de los mismos |
| US20240409558A1 (en) * | 2021-09-13 | 2024-12-12 | Biomea Fusion, Inc. | Irreversible inhibitors of kras |
| WO2023061294A1 (zh) * | 2021-10-13 | 2023-04-20 | 再鼎医药(上海)有限公司 | 含氮杂环类衍生物调节剂、其制备方法及应用 |
| WO2023072188A1 (zh) * | 2021-10-29 | 2023-05-04 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| EP4436571A4 (en) * | 2021-11-24 | 2025-10-15 | Merck Sharp & Dohme Llc | SMALL MOLECULE INHIBITORS OF KRAS MUTATIONAL PROTEINS |
| US20250250286A1 (en) * | 2021-11-30 | 2025-08-07 | Beta Pharma, Inc. | Fused pyrimidine derivatives as kras oncoprotein inhibitors |
| WO2023114733A1 (en) * | 2021-12-13 | 2023-06-22 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| WO2023137223A1 (en) * | 2022-01-17 | 2023-07-20 | Newave Pharmaceutical Inc. | Pan-kras inhibitors and uses thereof |
| CN118556063A (zh) * | 2022-01-21 | 2024-08-27 | 上海湃隆生物科技有限公司 | 杂环类化合物、药物组合物及其应用 |
| AU2023216698A1 (en) * | 2022-02-03 | 2024-06-13 | Mirati Therapeutics, Inc. | Quinazoline pan-kras inhibitors |
| CA3243798A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| MX2024010045A (es) * | 2022-02-16 | 2024-08-26 | Amgen Inc | Compuestos de quinazolina y uso de los mismos como inhibidores de proteinas mutantes kras. |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| AU2023231139A1 (en) | 2022-03-11 | 2024-09-05 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2023215802A1 (en) * | 2022-05-04 | 2023-11-09 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN117327102B (zh) * | 2022-06-30 | 2026-04-28 | 重庆华森英诺生物科技有限公司 | Kras抑制剂、其制备方法及应用 |
| WO2024008068A1 (en) * | 2022-07-04 | 2024-01-11 | Jacobio Pharmaceuticals Co., Ltd. | K-ras mutant protein inhibitors |
| WO2024008179A1 (en) * | 2022-07-07 | 2024-01-11 | Beigene, Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| IL318647A (en) | 2022-08-05 | 2025-03-01 | Kumquat Biosciences Inc | Heterocyclic compounds and their uses |
| WO2024041606A1 (zh) * | 2022-08-24 | 2024-02-29 | 泰励生物科技（上海）有限公司 | 具有抗kras突变肿瘤活性的化合物 |
| US20260083750A1 (en) * | 2022-08-26 | 2026-03-26 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| WO2024045066A1 (en) * | 2022-08-31 | 2024-03-07 | Nikang Therapeutics, Inc. | Alkylidene carbamate as kras inhibitors |
| EP4584276A1 (en) * | 2022-09-07 | 2025-07-16 | Bristol-Myers Squibb Company | Kras g12d inhibitors |
| WO2024054625A2 (en) * | 2022-09-08 | 2024-03-14 | Nikang Therapeutics, Inc. | Bifunctional compounds for degrading kras g12d via ubiquitin proteasome pathway |
| TW202416976A (zh) * | 2022-09-16 | 2024-05-01 | 大陸商南京明德新藥研發有限公司 | 含六氫螺環［環丙烷—１，２＇—吡咯𠯤］的化合物 |
| WO2024061365A1 (zh) * | 2022-09-22 | 2024-03-28 | 成都奥睿药业有限公司 | 嘧啶并环类化合物及其制备方法与用途 |
| WO2024063576A1 (ko) * | 2022-09-23 | 2024-03-28 | 일동제약(주) | Kras 저해 물질로서 신규한 퀴나졸린 화합물 |
| JP2025536369A (ja) | 2022-10-21 | 2025-11-05 | リーディングタック ファーマシューティカル（シャオシン）カンパニー，リミテッド | Ｋｒａｓ ｇ１２ｄ分解剤及びその製造方法並びに応用 |
| EP4631942A1 (en) | 2022-10-21 | 2025-10-15 | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Pan-kras degrading agent, and preparation method therefor and use thereof |
| TW202430179A (zh) | 2022-11-21 | 2024-08-01 | 美商樹線生物科學公司 | 螺環二氫哌喃并嘧啶ＫＲａｓ抑制劑 |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| KR20260041941A (ko) | 2023-03-15 | 2026-03-27 | 콴타 테라퓨틱스, 인크. | Kras 조절 인자 및 이의 용도 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CN118772151A (zh) * | 2023-04-04 | 2024-10-15 | 泰励生物科技（上海）有限公司 | 具有抗kras突变肿瘤活性的化合物 |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| CN121464140A (zh) | 2023-04-14 | 2026-02-03 | 锐新医药公司 | Ras抑制剂的结晶形式、含有其的组合物及其使用方法 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| CN121532183A (zh) * | 2023-05-15 | 2026-02-13 | 米拉蒂治疗公司 | Kras g12s和g12c抑制剂 |
| WO2025019823A1 (en) * | 2023-07-20 | 2025-01-23 | Merck Sharp & Dohme Llc | Small molecule protein degraders of kras g12d mutant |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025038936A1 (en) | 2023-08-17 | 2025-02-20 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| AU2024337016A1 (en) * | 2023-09-08 | 2026-04-16 | Tyligand Bioscience (Shanghai) Limited | Ras inhibitor |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AU2024361909A1 (en) | 2023-10-20 | 2026-03-26 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| TW202545934A (zh) * | 2024-02-05 | 2025-12-01 | 日商安斯泰來製藥股份有限公司 | 包含具有突變ｋｒａｓ蛋白分解誘導作用之雜環化合物的抗體藥物複合體 |
| WO2025170938A1 (en) * | 2024-02-06 | 2025-08-14 | Windermere Therapeutics, Inc. | Kras(g12d) inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025218811A1 (zh) * | 2024-04-19 | 2025-10-23 | 领泰生物医药(绍兴)有限公司 | pan-KRAS靶向蛋白降解剂及其制备方法和应用 |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190186A1 (ar) * | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
| PE20260440A1 (es) * | 2018-11-09 | 2026-02-19 | Hoffmann La Roche | Compuestos de anillo fusionado |
| EP3908283A4 (en) * | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| EP4225383A4 (en) * | 2020-10-08 | 2024-12-11 | Kumquat Biosciences Inc. | MODULATORS OF CELLULAR PROLIFERATION AND THEIR USES |
| CA3228338A1 (en) * | 2021-08-10 | 2023-02-16 | Amgen Inc. | Heterocyclic compounds and methods of use |
| EP4389751A1 (en) * | 2021-09-03 | 2024-06-26 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
-
2022
- 2022-02-09 EP EP22753296.7A patent/EP4291199A4/en not_active Withdrawn
- 2022-02-09 CA CA3207854A patent/CA3207854A1/en active Pending
- 2022-02-09 AU AU2022220678A patent/AU2022220678A1/en not_active Withdrawn
- 2022-02-09 WO PCT/US2022/015874 patent/WO2022173870A1/en not_active Ceased
- 2022-02-09 JP JP2023547848A patent/JP2024506329A/ja not_active Withdrawn
-
2023
- 2023-08-08 US US18/446,017 patent/US20240254129A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP4291199A1 (en) | 2023-12-20 |
| AU2022220678A1 (en) | 2023-09-21 |
| US20240254129A1 (en) | 2024-08-01 |
| JP2024506329A (ja) | 2024-02-13 |
| WO2022173870A1 (en) | 2022-08-18 |
| EP4291199A4 (en) | 2025-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3207854A1 (en) | Heterocyclic compounds and uses thereof | |
| EP3455204B1 (en) | Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors | |
| CN119032096A (zh) | 杂环化合物及其用途 | |
| CN114845997A (zh) | 芳香类化合物及其在制备抗肿瘤药物中的应用 | |
| UA130043C2 (uk) | Похідні хіноксаліну як протиракові лікарські засоби | |
| JP6313772B2 (ja) | チロシン受容体キナーゼｂｔｋ阻害剤である置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体 | |
| CN115335373A (zh) | 化合物及其用途 | |
| CA2934247A1 (en) | Tetrahydropyridopyrazine modulators of gpr6 | |
| BR112017004209B1 (pt) | Compostos derivados de tetrahidronaftaleno, composição farmacêutica e uso dos mesmos para inibir a proteína mcl-1 | |
| JP7618553B2 (ja) | ラパマイシン誘導体 | |
| JP5520236B2 (ja) | プロリン環構造を有するイミダゾチアゾール誘導体 | |
| BR112020019963A2 (pt) | Composto com atividade anticâncer | |
| CN116528869A (zh) | 氨基杂芳基激酶抑制剂 | |
| TW202402735A (zh) | Ｎ－（吡咯啶－３－基或哌啶－４－基）乙醯胺衍生物 | |
| KR102826811B1 (ko) | 키나아제 억제제로 작용하는 다환성 화합물 | |
| KR100935904B1 (ko) | 항바이러스성 약물의 말레산 단일염 및 이를 함유하는약제학적 조성물 | |
| WO2021222466A1 (en) | Heterocyclic compounds as bet inhibitors | |
| EP4121042A1 (en) | Tricyclic p2-ligand containing potent hiv-protease inhibitors | |
| CN115490686A (zh) | 一类含氮杂环化合物 | |
| US20230212122A1 (en) | Mitochondrial targeting compounds for the treatment of associated diseases | |
| RU2809763C2 (ru) | Соединение, обладающее противораковой активностью | |
| CN121419769A (zh) | 异双功能化合物及其使用方法 | |
| EA030947B1 (ru) | Способ крупномасштабного производства 1-изопропил-3-{5-[1-(3-метоксипропил)пиперидин-4-ил]-[1,3,4]оксадиазол-2-ил}-1h-индазола оксалата | |
| HK40111293A (en) | Menin inhibitor and use thereof | |
| CN121135702A (zh) | 含有杂环的衍生物及其组合物和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241206 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241206 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241206 |
|
| B11 | Application withdrawn |
Free format text: ST27 STATUS EVENT CODE: A-1-1-B10-B11-B206 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: WITHDRAWAL REQUEST RECEIVED Effective date: 20250627 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250702 |
|
| B11 | Application withdrawn |
Free format text: ST27 STATUS EVENT CODE: T-1-6-B10-B11-B202 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: WITHDRAWN Effective date: 20251210 |